It’s an initiative announced by the Food and Drug Administration (FDA) in August 2002, designed to evaluate,
improve, and modernize – to bring to 21st century level – the agency’s approach to reviews and inspections related to
the manufacturing of human and animal drugs and select human biological products, such as vaccines. As part of this
initiative, both the pharmaceutical and the chemistry, manufacturing, and controls (CMC) regulatory programs
were evaluated.
